Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Innate Pharma S.A. - American Depositary Shares
(NQ:
IPHA
)
2.195
-0.145 (-6.20%)
Streaming Delayed Price
Updated: 3:59 PM EST, Feb 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Innate Pharma S.A. - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Innate Pharma Announces Its Participation in Upcoming Investor Conference
August 01, 2024
From
Innate Pharma
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
July 25, 2024
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
June 18, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
June 17, 2024
From
Innate Pharma SA
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
June 10, 2024
Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning!
Via
InvestorPlace
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
June 04, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
May 28, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
May 24, 2024
From
Innate Pharma SA
Via
Business Wire
Outcome of Innate Pharma’s 2024 Annual General Meeting
May 23, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma: Clarification Regarding SAR443579 Designation
May 21, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
May 15, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
May 14, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
May 07, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
April 15, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
April 15, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
April 10, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Its Participation in Upcoming Investor Conference
April 09, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
April 05, 2024
From
Innate Pharma SA
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 03, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 01, 2024
Via
Benzinga
Earnings Scheduled For March 21, 2024
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
March 21, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Its Participation to Upcoming Investor Conference
March 19, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
March 14, 2024
From
Innate Pharma SA
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
March 11, 2024
Via
Benzinga
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
March 06, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
March 06, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Its Participation to Upcoming Investor Conference
February 21, 2024
From
Innate Pharma SA
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 06, 2024
Via
Benzinga
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
January 12, 2024
From
Innate Pharma S.A.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.